Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20253124 | 0.85 | FAAH (0.41) | LMNAL3MBTL1FAAHDPP4NPC1 | |
| SCHEMBL12335217 | 0.84 | LMNA (0.50) | LMNAL3MBTL1POLBHSD17B10ITGB3 | |
| SCHEMBL6521320 | 0.82 | POLB (0.53) | LMNAL3MBTL1POLBHSD17B10ITGB3 | |
| SCHEMBL19195080 | 0.81 | L3MBTL1 (0.50) | LMNAL3MBTL1POLBITGB3ITGA2B | |
| SCHEMBL13002469 | 0.81 | DPP4 (0.44) | FAAHDPP4NPC1ALDH1A1 | |
| SCHEMBL12384373 | 0.81 | FAAH (0.43) | FAAHDPP4NPC1ALDH1A1 | |
| SCHEMBL10146693 | 0.81 | ALDH1A1 (0.60) | LMNAFAAHDPP4NPC1RAB9A | |
| SCHEMBL12720521 | 0.81 | POLB (0.38) | LMNAPOLBFAAH | |
| SCHEMBL12308823 | 0.80 | LMNA (0.46) | LMNAL3MBTL1POLBHSD17B10ITGB3 | |
| SCHEMBL13965734 | 0.80 | HRH3 (0.55) | HSD17B10FAAHSMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-20190161471-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-10202362-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORA, RORC, RORB | LMNA 4672/4885L3MBTL1 4845/4885POLB 4324/4885 |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | LMNA 3529/4885L3MBTL1 1081/4885POLB 1461/4885 |
| US-20190161471-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LMNA 1225/4885L3MBTL1 1450/4885POLB 2412/4885 |
| US-20180162836-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LMNA 1225/4885L3MBTL1 1450/4885POLB 2412/4885 |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | LMNA 779/4885L3MBTL1 503/4885POLB 4833/4885 |
| US-10202362-B2 | Inhibitors of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R | LMNA 1225/4885L3MBTL1 1450/4885POLB 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.